178 related articles for article (PubMed ID: 36708070)
1. Identification of EMP1 as a critical gene for cisplatin resistance in ovarian cancer by using integrated bioinformatics analysis.
Zeng Q; Yi C; Lu J; Wang X; Chen K; Hong L
Cancer Med; 2023 Apr; 12(7):9024-9040. PubMed ID: 36708070
[TBL] [Abstract][Full Text] [Related]
2. MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A.
Wang J; Liu L
J Ovarian Res; 2021 Nov; 14(1):165. PubMed ID: 34798882
[TBL] [Abstract][Full Text] [Related]
3. SORL1 stabilizes ABCB1 to promote cisplatin resistance in ovarian cancer.
Zheng Z; Li X; Yang B; Xu Q; Zhu X; Hu L; Teng Y
Funct Integr Genomics; 2023 May; 23(2):147. PubMed ID: 37145301
[TBL] [Abstract][Full Text] [Related]
4. Bioinformatics analysis of mRNA and miRNA microarray to identify the key miRNA-mRNA pairs in cisplatin-resistant ovarian cancer.
Xue B; Li S; Jin X; Liu L
BMC Cancer; 2021 Apr; 21(1):452. PubMed ID: 33892654
[TBL] [Abstract][Full Text] [Related]
5. EMP1 correlated with cancer progression and immune characteristics in pan-cancer and ovarian cancer.
Zhang J; Yang J; Li X; Mao L; Zhang Y; Liu Y; Bao Y
Mol Genet Genomics; 2024 May; 299(1):51. PubMed ID: 38743077
[TBL] [Abstract][Full Text] [Related]
6. Reduced RBPMS Levels Promote Cell Proliferation and Decrease Cisplatin Sensitivity in Ovarian Cancer Cells.
Rabelo-Fernández RJ; Santiago-Sánchez GS; Sharma RK; Roche-Lima A; Carrion KC; Rivera RAN; Quiñones-Díaz BI; Rajasekaran S; Siddiqui J; Miles W; Rivera YS; Valiyeva F; Vivas-Mejia PE
Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008958
[TBL] [Abstract][Full Text] [Related]
7. Silencing of miR-1246 Induces Cell Cycle Arrest and Apoptosis in Cisplatin-Resistant Ovarian Cancer Cells by Promoting ZNF23 Transcription.
Cai L; Zhang Q; Du L; Zheng F
Cytogenet Genome Res; 2021; 161(10-11):488-500. PubMed ID: 34923485
[TBL] [Abstract][Full Text] [Related]
8. Reversal of cisplatin resistance by microRNA-139-5p-independent RNF2 downregulation and MAPK inhibition in ovarian cancer.
Chen Y; Cao XY; Li YN; Qiu YY; Li YN; Li W; Wang H
Am J Physiol Cell Physiol; 2018 Aug; 315(2):C225-C235. PubMed ID: 29719173
[TBL] [Abstract][Full Text] [Related]
9. Cross‑validation of genes potentially associated with neoadjuvant chemotherapy and platinum‑based chemoresistance in epithelial ovarian carcinoma.
Zhang K; Wang W; Chen L; Liu Y; Hu J; Guo F; Tian W; Wang Y; Xue F
Oncol Rep; 2020 Sep; 44(3):909-926. PubMed ID: 32705213
[TBL] [Abstract][Full Text] [Related]
10. Integrated bioinformatics analysis for the screening of hub genes and therapeutic drugs in ovarian cancer.
Yang D; He Y; Wu B; Deng Y; Wang N; Li M; Liu Y
J Ovarian Res; 2020 Jan; 13(1):10. PubMed ID: 31987036
[TBL] [Abstract][Full Text] [Related]
11. Long non-coding RNA Linc00312 modulates the sensitivity of ovarian cancer to cisplatin via the Bcl-2/Caspase-3 signaling pathway.
Zhang C; Wang M; Shi C; Shi F; Pei C
Biosci Trends; 2018 Jul; 12(3):309-316. PubMed ID: 29952351
[TBL] [Abstract][Full Text] [Related]
12. Toosendanin reduces cisplatin resistance in ovarian cancer through modulating the miR-195/ERK/β-catenin pathway.
Wang G; Li L; Li Y; Zhang LH
Phytomedicine; 2023 Jan; 109():154571. PubMed ID: 36610147
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of microRNA-195-5p reduces cisplatin resistance and angiogenesis in ovarian cancer by inhibiting the PSAT1-dependent GSK3β/β-catenin signaling pathway.
Dai J; Wei R; Zhang P; Kong B
J Transl Med; 2019 Jun; 17(1):190. PubMed ID: 31171023
[TBL] [Abstract][Full Text] [Related]
14. Identification of an Immune Gene-Based Cisplatin Response Model and CD27 as a Therapeutic Target against Cisplatin Resistance for Ovarian Cancer.
Guo Y; Yang N; Li G; Yin X; Dong L
J Immunol Res; 2022; 2022():4379216. PubMed ID: 35647204
[TBL] [Abstract][Full Text] [Related]
15. Long non-coding RNA CTSLP8 mediates ovarian cancer progression and chemotherapy resistance by modulating cellular glycolysis and regulating c-Myc expression through PKM2.
Li X; Zhang Y; Wang X; Lin F; Cheng X; Wang Z; Wang X
Cell Biol Toxicol; 2022 Dec; 38(6):1027-1045. PubMed ID: 34510316
[TBL] [Abstract][Full Text] [Related]
16. Downregulated expression levels of USP46 promote the resistance of ovarian cancer to cisplatin and are regulated by PUM2.
Xu L; Zhang B; Li W
Mol Med Rep; 2021 Apr; 23(4):. PubMed ID: 33576437
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of LINC01508 contributes to cisplatin resistance in ovarian cancer via the regulation of the Hippo-YAP pathway.
Xiao L; Shi XY; Li ZL; Li M; Zhang MM; Yan SJ; Wei ZL
J Gynecol Oncol; 2021 Sep; 32(5):e77. PubMed ID: 34132072
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-95-3p serves as a contributor to cisplatin resistance in human gastric cancer cells by targeting EMP1/PI3K/AKT signaling.
Ni Q; Zhang Y; Tao R; Li X; Zhu J
Aging (Albany NY); 2021 Mar; 13(6):8665-8687. PubMed ID: 33714198
[TBL] [Abstract][Full Text] [Related]
19. MiR-1294 confers cisplatin resistance in ovarian Cancer cells by targeting IGF1R.
Zhang Y; Huang S; Guo Y; Li L
Biomed Pharmacother; 2018 Oct; 106():1357-1363. PubMed ID: 30119207
[TBL] [Abstract][Full Text] [Related]
20. Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer.
Ehlén A; Brennan DJ; Nodin B; O'Connor DP; Eberhard J; Alvarado-Kristensson M; Jeffrey IB; Manjer J; Brändstedt J; Uhlén M; Pontén F; Jirström K
J Transl Med; 2010 Aug; 8():78. PubMed ID: 20727170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]